Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Acumen Pharmaceuticals, Inc.
< Previous
1
2
Next >
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
March 12, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
March 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
February 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
February 01, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
November 07, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
November 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
November 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
November 02, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
October 27, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
October 04, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
September 19, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
September 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
August 01, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Announces Pricing of Upsized $130 Million Public Offering
July 18, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
July 17, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
July 17, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023
July 16, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023
June 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference
May 04, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
May 02, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease
March 28, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights
March 27, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days
March 22, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
March 20, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum
March 08, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ABOS
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.